BMS pulls sBLA for Opdivo/Yervoy combo in first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said it has voluntarily withdrawn its sBLA for anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line treatment of lung cancer, citing a need for more evidence of the relationship between PD-L1 and

Read the full 393 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE